Anti-Tissue Factor Antibody-Drug Conjugates for Selective Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapies with an acceptable safety profile and high efficacy for treating cancers expressing tissue factor, particularly gynecological and head and neck cancers.
Innovation Solution
Administering an anti-Tissue Factor (anti-TF) antibody-drug conjugate, such as tisotumab vedotin, in combination with radiation therapy and optionally a platinum-based chemotherapeutic agent, to target and treat cancers positive for tissue factor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then treatment coverage is broad, but efficacy against TF-expressing cancers is insufficient and safety profile is compromised
Solution Approach 1:
The antibody-drug conjugate delivers cytotoxic payload specifically to TF-expressing cancer cells through targeted binding, concentrating therapeutic effect at the disease site while sparing healthy tissues. This localized action resolves the contradiction by improving efficacy where needed without compromising overall safety.
Solution Approach 2:
The anti-TF antibody serves as an intermediary that selectively delivers the cytotoxic drug (monomethyl auristatin) only to TF-expressing cells. This mediator approach enables precise targeting of malignant cells while avoiding widespread toxicity, thus improving reliability without worsening safety profile.
2Reliability
If combination therapy with multiple agents is used, then treatment efficacy is improved, but treatment complexity increases
Solution Approach 1:
The invention merges the targeting function (anti-TF antibody) and the therapeutic function (cytotoxic drug) into a single conjugate molecule. This combination achieves the efficacy benefits of multi-agent therapy while simplifying the treatment regimen to a single administered agent, resolving the contradiction between efficacy and complexity.
Solution Approach 2:
The antibody-drug conjugate represents a composite therapeutic agent combining biological targeting moiety with chemical cytotoxic agent. This composite structure integrates multiple functional elements into one molecule, achieving synergistic effects without the logistical complexity of separate administrations.
3Reliability
If high doses of cytotoxic agents are used, then tumor killing efficacy is enhanced, but toxicity to healthy tissues increases
Solution Approach 1:
The conjugate delivers high concentrations of cytotoxic agent specifically to TF-expressing tumor cells while maintaining low systemic exposure. This localized high-dose delivery achieves effective tumor killing without proportionally increasing toxicity to healthy tissues, resolving the contradiction between efficacy and safety.
Solution Approach 2:
The anti-TF antibody acts as a selective intermediary that carries the cytotoxic drug only to target cells. This enables administration of cytotoxic doses without widespread tissue exposure, as the antibody mediator prevents non-specific distribution and off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively reduces tumor size and improves survival rates in head and neck squamous cell carcinoma and gynecological cancers by selectively targeting TF-expressing cells, enhancing treatment efficacy.
Implementation Method 1
an anti-Tissue Factor (anti-TF) antibody-drug conjugate that binds to tissue factor (TF)
Implementation Method 2
the antibody-drug conjugate comprises an anti-TF antibody or an antigen-binding fragment thereof conjugated to an auristatin or a functional analog thereof
Implementation Method 3
administering to the subject a radiation therapy
Data Source
AI summary
The disclosure provides antibody-drug conjugates that bind to tissue factor (TF) (e.g, tisotumab vedotin) and its use in methods of treating cancer, such as head and neck squamous cell carcinoma or a gynecological cancer, including in combination with a radiation therapy. The disclosure also provides antibody-drug conjugates that bind to TF for use in combination with an additional chemotherapeutic, such as a platinum-based agent (e.g., carboplatin or cisplatin), including in combination with a radiation therapy, for treating cancer.